In vivo activation of T-cell induction into the primed phenotype and programmed cell death by staphylococcal enterotoxin B. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


In vivo activation of T-cell induction into the primed phenotype and programmed cell death by staphylococcal enterotoxin B.

Scand J Immunol. 1996 May;43(5):545-50. Unique Identifier : AIDSLINE MED/96233696
Aroeira LS; Moreno MC; Martinez C; Department of Immunology and Oncology, Universidad Autonoma de; Madrid, Spain.

Abstract: The authors demonstrate that SEB immunization activates V beta 8+ T cells and induces the acquisition of the primed phenotype as defined previously by low MEL-14 and high Pgp-1 expression. SEB-activated spleen CD4+ and CD8V beta 8+ T cells have different population dynamics and regulate the expression of MEL-14 and Pgp-1 differentially, suggesting that the SEB-MHC class II complex preferentially activates CD4V beta 8+ T cells. Interestingly, at day 3 after SEB immunization, V beta 8+ T cells expressing low, but not high, levels of MEL-14 undergo apoptosis, indicating that T-cell activation is a prerequisite for triggering programmed cell death. These results might help to trace antigen-reactive cells to the activated or primed pool, as well as to identify those cells which will undergo programmed cell death.
Keywords: Animal Apoptosis/*IMMUNOLOGY Cell Cycle CD8-Positive T-Lymphocytes/CYTOLOGY Enterotoxins/*PHARMACOLOGY Female Lymphocyte Transformation/GENETICS/*PHYSIOLOGY Male Mice Mice, Inbred BALB C Phenotype Staphylococcus aureus/IMMUNOLOGY Superantigens/PHARMACOLOGY Support, Non-U.S. Gov't T-Lymphocytes/*IMMUNOLOGY JOURNAL ARTICLEKWDanimalapoptosis/KWDimmunologycellcyclecd8-positivet-lymphocytes/cytologyenterotoxins/KWDpharmacologyfemalelymphocytetransformation/genetics/KWDphysiologymalemicemice,inbredbalbcphenotypestaphylococcusaureus/immunologysuperantigens/pharmacologysupport,non-uKWDsKWDgov'tt-lymphocytes/KWDimmunologyjournalarticle
960930
M9690877

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .